Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.
We all know the old adage “measure twice, cut once” but sometimes taking the time to confirm your measurements eats up ...